Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the Pharma & Biotech edition of the IP Thinktank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: http://thinkipstrategy.com/subscribe/

Cipro (Ciprofloxacin) – US: CAFC finds no antitrust liability for Hatch-Waxman reverse payment settlements: In Re Ciproflaxacin Hydrochloride Antitrust Litigation (Law360) (Patently-O) (Hal Wegner) (SmartBrief) (GenericsWeb) (Patent Prospector) (PLI)

Coversyl (Perindopril) – UK: Calculating damages on a cross-undertaking in patents: Les Laboratoires Servier & Anor v Apotex Inc & Ors (IPKat) (IP finance) (GenericsWeb)

Zyprexa (Olanzapine) – UK: ‘selection patent’ doctrine briefly back in the limelight: Dr Reddy’s Laboratories (UK) Ltd v Eli Lilly & Co Ltd (IPKat) (Hal Wegner)

Canada: The Hills Times Policy Briefing on Biotechnology (Pharmacapsules)

EU: EPIPAGRI develops IPR database in the field of agricultural biotechnology and related industry (IPR-Helpdesk)

EU: Access to information or promotion! Proposed EU information laws on prescription drugs (IPmed)

Iceland: Supplementary Protection Certificates (SPCs) in Iceland (The SPC blog)

India: Roche implements ‘mass serialisation’ anti-counterfeiting technology (Spicy IP)

Indonesia: Patent application on oil palm hybrids (navigating the patent maze)

United States: New PMCA research: State legislative proposals restricting access to generic medicines would increase cost $29 billion over 10 years (GenericsWeb)

US: Pharmaceutical patent laws: a prescription for success in challenging times (FDA Law Blog)

Abilify (Aripiprazole) – US: Protective order for Apotex employees mostly denied in patent suit over Abilify (Law360)

Cipro (Ciprofloxacin) – US: CAFC finds no antitrust liability for Hatch-Waxman reverse payment settlements: In Re Ciproflaxacin Hydrochloride Antitrust Litigation (Law360) (Patently-O) (Hal Wegner) (SmartBrief) (GenericsWeb) (Patent Prospector) (PLI)

Cosopt/Trusopt (Dorzolamide) – US: Federal Circuit affirms dismissal of declaratory judgment counterclaims in Merck & Co v Apotex (Orange Book Blog)

Coversyl (Perindopril) – UK: Calculating damages on a cross-undertaking in patents: Les Laboratoires Servier & Anor v Apotex Inc & Ors (IPKat) (IP finance) (GenericsWeb)

Lovenox (Enoxaparin) – US: Strike 4 – Lovenox patent still unenforceable: Aventis v Sandoz (PATracer)

Mircera (Methoxy polyethylene glycol-epoetin beta) – US: Trial judge grants permanent injunction in case relating to recombinant erythropoietin (EPO) patent: Amgen v F Hoffmann-LaRoche: (Patent Docs) (Patent Docs) (Patent Docs)

Nexium (Esomeprazole) – US: AstraZeneca sues Ivax, Teva over Nexium patent (Law360)

Rilutek (Riluzole) – US: Prior art must enable a skilled artisan to make the invention without undue experimentation: Impax Labs v Aventis Pharmaceuticals (Patent Baristas)

Zovirax (Aciclovir) – EU: AG Sharpston delivers opinion in trade mark infringement and pharmaceutical repackaging case: Wellcome Foundation Ltd v Paranova Pharmazeutika Handels GmbH (Class 46)

Zyprexa (Olanzapine) – UK: ‘selection patent’ doctrine briefly back in the limelight: Dr Reddy’s Laboratories (UK) Ltd v Eli Lilly & Co Ltd (IPKat) (Hal Wegner)